These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 30366005)
1. The novel psychoactive substance methoxetamine induces persistent behavioral abnormalities and neurotoxicity in rats. Costa G; Serra M; Pintori N; Casu MA; Zanda MT; Murtas D; De Luca MA; Simola N; Fattore L Neuropharmacology; 2019 Jan; 144():219-232. PubMed ID: 30366005 [TBL] [Abstract][Full Text] [Related]
2. Methoxetamine affects brain processing involved in emotional response in rats. Zanda MT; Fadda P; Antinori S; Di Chio M; Fratta W; Chiamulera C; Fattore L Br J Pharmacol; 2017 Oct; 174(19):3333-3345. PubMed ID: 28718892 [TBL] [Abstract][Full Text] [Related]
3. New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT Marti M; Talani G; Miliano C; Bilel S; Biggio F; Bratzu J; Diana M; De Luca MA; Fattore L Exp Neurol; 2021 Nov; 345():113836. PubMed ID: 34384790 [TBL] [Abstract][Full Text] [Related]
4. R (-)-methoxetamine exerts rapid and sustained antidepressant effects and fewer behavioral side effects relative to S (+)-methoxetamine. Botanas CJ; Perez Custodio RJ; Kim HJ; de la Pena JB; Sayson LV; Ortiz DM; Kim M; Lee HJ; Acharya S; Kim KM; Lee CJ; Ryu JH; Lee YS; Cheong JH Neuropharmacology; 2021 Aug; 193():108619. PubMed ID: 34023336 [TBL] [Abstract][Full Text] [Related]
5. Neurological, sensorimotor and cardiorespiratory alterations induced by methoxetamine, ketamine and phencyclidine in mice. Ossato A; Bilel S; Gregori A; Talarico A; Trapella C; Gaudio RM; De-Giorgio F; Tagliaro F; Neri M; Fattore L; Marti M Neuropharmacology; 2018 Oct; 141():167-180. PubMed ID: 30165078 [TBL] [Abstract][Full Text] [Related]
6. Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat. Horsley RR; Lhotkova E; Hajkova K; Jurasek B; Kuchar M; Palenicek T Brain Res Bull; 2016 Sep; 126(Pt 1):102-110. PubMed ID: 27155360 [TBL] [Abstract][Full Text] [Related]
7. The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission. Mutti A; Aroni S; Fadda P; Padovani L; Mancini L; Collu R; Muntoni AL; Fattore L; Chiamulera C Psychopharmacology (Berl); 2016 Jun; 233(12):2241-51. PubMed ID: 27020786 [TBL] [Abstract][Full Text] [Related]
9. Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: Evidence of its abuse potential. Botanas CJ; de la Peña JB; Dela Peña IJ; Tampus R; Yoon R; Kim HJ; Lee YS; Jang CG; Cheong JH Pharmacol Biochem Behav; 2015 Jun; 133():31-6. PubMed ID: 25792291 [TBL] [Abstract][Full Text] [Related]
10. Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Zanda MT; Fadda P; Chiamulera C; Fratta W; Fattore L Behav Pharmacol; 2016 Sep; 27(6):489-96. PubMed ID: 27128862 [TBL] [Abstract][Full Text] [Related]
11. Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB₁ cannabinoid receptors. Bortolato M; Frau R; Bini V; Luesu W; Loriga R; Collu M; Gessa GL; Ennas MG; Castelli MP J Psychiatr Res; 2010 Oct; 44(14):944-55. PubMed ID: 20378129 [TBL] [Abstract][Full Text] [Related]
12. Phencyclidine-like in vivo effects of methoxetamine in mice and rats. Berquist MD; Hyatt WS; Bauer-Erickson J; Gannon BM; Norwood AP; Fantegrossi WE Neuropharmacology; 2018 May; 134(Pt A):158-166. PubMed ID: 28830759 [TBL] [Abstract][Full Text] [Related]
13. Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice. Lin Z; Dodd CA; Filipov NM Neurotoxicol Teratol; 2013; 39():26-35. PubMed ID: 23770127 [TBL] [Abstract][Full Text] [Related]
14. A new synthetic drug 5-(2-aminopropyl)indole (5-IT) induces rewarding effects and increases dopamine D1 receptor and dopamine transporter mRNA levels. Botanas CJ; Yoon SS; de la Peña JB; Dela Peña IJ; Kim M; Custodio RJ; Woo T; Seo JW; Jang CG; Yang JS; Yoon YM; Lee YS; Kim HJ; Cheong JH Behav Brain Res; 2018 Apr; 341():122-128. PubMed ID: 29288746 [TBL] [Abstract][Full Text] [Related]
15. Methoxetamine produces rapid and sustained antidepressant effects probably via glutamatergic and serotonergic mechanisms. Botanas CJ; Bryan de la Peña J; Custodio RJ; Joy Dela Peña I; Kim M; Woo T; Kim HJ; Kim HI; Chang Cho M; Lee YS; Cheong JH Neuropharmacology; 2017 Nov; 126():121-127. PubMed ID: 28867363 [TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter, but not tyrosine hydroxylase, may be implicated in determining individual differences in behavioral sensitization to amphetamine. Dietz DM; Tapocik J; Gaval-Cruz M; Kabbaj M Physiol Behav; 2005 Oct; 86(3):347-55. PubMed ID: 16126238 [TBL] [Abstract][Full Text] [Related]
18. Methoxetamine: A foe or friend? Botanas CJ; de la Peña JB; Kim HJ; Lee YS; Cheong JH Neurochem Int; 2019 Jan; 122():1-7. PubMed ID: 30365979 [TBL] [Abstract][Full Text] [Related]
19. 25C-NBF, a new psychoactive substance, has addictive and neurotoxic potential in rodents. Hur KH; Kim SE; Lee BR; Ko YH; Seo JY; Kim SK; Ma SX; Kim YJ; Jeong Y; Pham DT; Trinh QD; Shin EJ; Kim HC; Lee YS; Lee SY; Jang CG Arch Toxicol; 2020 Jul; 94(7):2505-2516. PubMed ID: 32296860 [TBL] [Abstract][Full Text] [Related]
20. Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence. Cadoni C; Pisanu A; Simola N; Frau L; Porceddu PF; Corongiu S; Dessì C; Sil A; Plumitallo A; Wardas J; Di Chiara G Neuropharmacology; 2017 Sep; 123():385-394. PubMed ID: 28603026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]